Chokeberry ( A. melanocarpa (Michx.) Elliott)-A Natural Product for Metabolic Disorders?
Ewa OlechnoAnna Puścion-JakubikMałgorzata Elżbieta ZujkoPublished in: Nutrients (2022)
Abnormal metabolism of substances in the body can result in metabolic disorders which include obesity, cardiovascular diseases, diabetes, hypertension, chronic kidney disease, liver disease, or cancer. Foods rich in antioxidants can help to prevent and treat various types of disorders. Chokeberry fruits are rich in polyphenols, especially cyanidins, and therefore, can show a beneficial health effect. The aim of this study was to summarize and systematize reports about the effects of chokeberry on various metabolic parameters. Studies from 2000 to 2021, published in the PubMed and Google Scholar databases, were reviewed. The review of studies shows that chokeberry may have a positive effect in dyslipidemia and hypertension and may increase the body's antioxidant defense mechanisms. The anti-inflammatory effect, in turn, may translate into a reduction in the risk of metabolic disorders over a longer period of use. Changes in glucose levels were reported by studies in which the intervention lasted more than 10 weeks in patients with carbohydrate metabolism disorders. The effects of protecting the liver, inhibiting platelet aggregation, lowering uric acid levels, and having a protective effect on the kidneys require additional confirmation in human clinical trials. Consumption of chokeberry fruit did not impact on anthropometric measurements; however, it seems that chokeberry fruit can be recommended in many metabolic disorders due to the richness of bioactive ingredients.
Keyphrases
- uric acid
- clinical trial
- chronic kidney disease
- cardiovascular disease
- blood pressure
- metabolic syndrome
- anti inflammatory
- type diabetes
- randomized controlled trial
- healthcare
- endothelial cells
- oxidative stress
- squamous cell carcinoma
- insulin resistance
- big data
- physical activity
- machine learning
- body composition
- drinking water
- risk assessment
- artificial intelligence
- weight gain
- case control
- skeletal muscle
- living cells
- adverse drug
- glycemic control
- phase iii
- arterial hypertension